EANS-News: Epigenomics AG Epigenomics AG Successfully Completes Capital
Increase
--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------
Subtitle: Not for distribution in the United States
Restructuring & Recapitalisations/molecular diagnostics
Berlin, Germany, and Seattle, WA, U.S.A. (euro adhoc) - Epigenomics AG
(Frankfurt Prime Standard: ECX), the German-American cancer molecular
diagnostics company, today announced the successful completion of a capital
increase by way of a rights issue and a subsequent private placement. Gross
proceeds amount to EUR 4,976,099, extending, based upon current projections, the
cash runway of the Company at least into Q4 2013.
In line with previous announcements, and supported by the recent submission of
its Premarket Approval (PMA) to the United States Food & Drug Administration
(FDA) for its blood-based Epi proColon® test for the detection of colorectal
cancer in December 2012, Epigenomics will continue to explore all strategic
options for the Company. These options especially include the possibility of
securing additional financial resources to support the Company's operations up
to and beyond a potential U.S. Food and Drug Administration (FDA) approval for
Epi proColon®.
Dr. Thomas Taapken, Chief Financial Officer and acting Chief Executive Officer
of Epigenomics, commented: "We are pleased about the outcome of this financing
and thank all of our shareholders and new investors who participated in the
capital increase. The completion of the PMA submission to the FDA by year end
2012 and the proceeds of this financing bring the Company closer to potential
FDA approval for Epi proColon®, while alleviating our financial situation."
Transaction outline:
On January 25, 2013, the Executive Board of Epigenomics AG, Berlin, Germany
(Frankfurt Prime Standard: ECX; ISIN: DE000A1K0516), with the approval of the
Supervisory Board, has taken the decision to implement the capital increase from
authorized capital, the details of which were announced on January 7, 2013, for
the maximum number of 3,149,430 new ordinary bearer shares, generating gross
proceeds of EUR 4,976,099.
2,811,707 new ordinary bearer shares were taken up by the shareholders at a
subscription price of EUR 1.58 per new share during the subscription period
which started on January 11, 2013 and ended on January 24, 2013. The remaining
337,723 unsubscribed new shares were sold at the subscription price of EUR 1.58
per new share in a private placement to institutional investors. The private
placement was significantly oversubscribed, enabling Epigenomics AG to place the
maximum number of new shares. The capital increase was conducted by Kempen & Co.
The registration of the implementation of the capital increase with the
commercial register ("Handelsregister") and the admission of the new shares to
the regulated market ("regulierter Markt"), Prime Standard, of the Frankfurt
Stock Exchange are expected on or around January 29, 2013. Trading in the new
shares is expected to begin on January 30, 2013, and delivery of the new shares
to the investors is expected on January 31, 2013. With the registration of the
implementation of the capital increase the total issued share capital of
Epigenomics increases from EUR 8,818,417.00 to EUR 11,967,847.00.
Epigenomics AG intends to use the net proceeds from the share capital increase
to finance its current operations.
- Ends -
Contact Epigenomics AG
Antje Zeise
Manager IR | PR
Epigenomics AG
Tel +49 (0) 30 24345 368
ir@epigenomics.comwww.epigenomics.com
About Epigenomics
Epigenomics (www.epigenomics.com) is a molecular diagnostics company developing
and commercializing a pipeline of proprietary products for cancer. The Company's
products enable doctors to diagnose cancer earlier and more accurately, leading
to improved outcomes for patients. Epigenomics' lead product, Epi proColon®, is
a blood-based test for the early detection of colorectal cancer, which is
currently marketed in Europe and is in development for the U.S.A. The Company's
technology and products have been validated through multiple partnerships with
leading global diagnostic companies including Abbott, QIAGEN, Sysmex, and Quest
Diagnostics. Epigenomics is an international company with operations in Europe
and the U.S.A.
Epigenomics legal disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Epigenomics AG and its business. Such statements involve
certain known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or achievements of
Epigenomics AG to be materially different from any future results, performance
or achievements expressed or implied by such forward-looking statements.
Epigenomics AG is providing this communication as of this date and does not
undertake to update any forward-looking statements contained herein as a result
of new information, future events or otherwise.
The information contained in this communication does not constitute nor imply an
offer to sell or transfer any product, and no product based on this technology
is currently available for sale by Epigenomics in the United States or Canada.
The analytical and clinical performance characteristics of any Epigenomics
product based on this technology which may be sold at some future time in the
U.S. have not been established.
Further inquiry note:
Antje Zeise | CIRO
Manager IR/PR
Epigenomics AG
Tel: +49 30 24345 386
end of announcement euro adhoc
--------------------------------------------------------------------------------
company: Epigenomics AG
Kleine Präsidentenstraße 1
D-10178 Berlin
phone: +49 30 24345-0
FAX: +49 30 24345-555
mail: ir@epigenomics.com
WWW: http://www.epigenomics.com
sector: Biotechnology
ISIN: DE000A1K0516
indexes: Prime All Share, Technology All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
regulated dealing/prime standard: Frankfurt
language: English